Results 91 to 100 of about 66,048 (291)

Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni   +3 more
wiley   +1 more source

Think highly of immunoglobulin G4‐related chronic rhinosinusitis as a clinical entity in immunoglobulin G4‐related disease

open access: yesEye &ENT Research, EarlyView.
Abstract IgG4‐related chronic rhinosinusitis (IgG4‐related CRS) is gaining recognition among various specialized physicians. As a systemic disease involving multiple organs, IgG4‐related CRS is still not widely recognized as an independent clinical entity. Given the complexity of diagnosing autoimmune‐related multisystem diseases, early recognition and
Lianqi Wan   +3 more
wiley   +1 more source

Clinical impact of follow‐up endomyocardial biopsy in myocarditis during or after immune‐suppressive therapy

open access: yesESC Heart Failure, EarlyView.
Results and clinical implication of repeat endomyocardial biopsy (EMB). Abstract Aims While the diagnostic role of endomyocardial biopsy (EMB) in myocarditis is unquestioned, little is known about its indications and clinical value during long‐term follow‐up.
Anna Baritussio   +12 more
wiley   +1 more source

Four decades of heart–lung transplantation: Milestones and outcomes in advanced cardiorespiratory failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Heart–lung transplantation (HLTx) remains a life‐saving intervention for patients with end‐stage cardiopulmonary failure. We retrospectively analysed long‐term HLTx outcomes at our centre to assess survival trends and evaluate the impact of evolving immunosuppressive, surgical and perioperative strategies.
L. Lily Rosenthal   +10 more
wiley   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Current and emerging treatment options in the management of lupus

open access: yesImmunoTargets and Therapy, 2016
Natasha Jordan,1 David D’Cruz2 1Department of Rheumatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, 2Louise Coote Lupus Unit, Guy’s and St Thomas’ Hospital NHS Foundation Trust, London, UK Abstract: Systemic ...
Jordan N, D’Cruz D
doaj  

Outcome Predictors of Generalized Myasthenia Gravis: A Prospective Observational Study

open access: yesAnnals of Indian Academy of Neurology
Background and Objectives: There is paucity of studies on long-term remission of autoimmune generalized myasthenia gravis (MG) from Southeast Asia. We report the outcome predictors of generalized MG and also evaluate the influence of high- versus low ...
Jayantee Kalita   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy